Retrospective Study of Hyponatremia in Gastric Cancer Patients Treated with a Combination Chemotherapy of 5-Fluorouracil and Cisplatin: a Possible Warning Sign of Severe Hematological Toxicities?
Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance. The subjects were 50 advanced gastric cancer pa...
Saved in:
Published in | Japanese journal of clinical oncology Vol. 31; no. 8; pp. 382 - 387 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
England
Oxford Publishing Limited (England)
01.08.2001
|
Subjects | |
Online Access | Get full text |
ISSN | 1465-3621 0368-2811 1465-3621 |
DOI | 10.1093/jjco/hye085 |
Cover
Abstract | Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance.
The subjects were 50 advanced gastric cancer patients treated with FP. Patients' performance status, oral intake, nausea/vomiting, diarrhea, fever, urine volume, presence of ascites or pleural effusion, laboratory data and administration of diuretics, corticosteroid and contents and volume of hydration before and during the first 5 days after chemotherapy were reviewed.
The serum sodium level decreased after initiation of chemotherapy in all patients and the lowest level (nadir) was most frequently observed on day 8 (range, days 2-14), which preceded hematological toxicities. In 10 patients (20%) the nadir of serum sodium was lower than 125 mEq/l. We classified these 10 patients as a low-sodium group and the others into a normal-sodium group. Six (60%) and seven (70%) of the 10 patients in the low-sodium group had complications with grade 3 or 4 leukopenia and thrombocytopenia, whereas only one (3%) and two (5%) were seen in the normal-sodium group (p < 0.0001). Stomatitis and diarrhea were also slightly more severe in the former than the latter group. With respect to sensitivity and probability, receiver operating characteristic curves showed the nadir ((> or = ) or <125 mEq/l) of the serum sodium level was the best marker for both leukopenia and thrombocytopenia.
Hyponatremia after initiation of chemotherapy with FP may be a warning sign of subsequent severe hematological toxicity. |
---|---|
AbstractList | Background: Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance. Methods: The subjects were 50 advanced gastric cancer patients treated with FP. Patients' performance status, oral intake, nausea/vomiting, diarrhea, fever, urine volume, presence of ascites or pleural effusion, laboratory data and administration of diuretics, corticosteroid and contents and volume of hydration before and during the first 5 days after chemotherapy were reviewed. Results: The serum sodium level decreased after initiation of chemotherapy in all patients and the lowest level (nadir) was most frequently observed on day 8 (range, days 2-14), which preceded hematological toxicities. In 10 patients (20%) the nadir of serum sodium was lower than 125 mEq/l. We classified these 10 patients as a low-sodium group and the others into a normal-sodium group. Six (60%) and seven (70%) of the 10 patients in the low-sodium group had complications with grade 3 or 4 leukopenia and thrombocytopenia, whereas only one (3%) and two (5%) were seen in the normal-sodium group (p < 0.0001). Stomatitis and diarrhea were also slightly more severe in the former than the latter group. With respect to sensitivity and probability, receiver operating characteristic curves showed the nadir (> or = or <125 mEq/l) of the serum sodium level was the best marker for both leukopenia and thrombocytopenia. Conclusion: Hyponatremia after initiation of chemotherapy with FP may be a warning sign of subsequent severe hematological toxicity. Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance.BACKGROUNDSome anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance.The subjects were 50 advanced gastric cancer patients treated with FP. Patients' performance status, oral intake, nausea/vomiting, diarrhea, fever, urine volume, presence of ascites or pleural effusion, laboratory data and administration of diuretics, corticosteroid and contents and volume of hydration before and during the first 5 days after chemotherapy were reviewed.METHODSThe subjects were 50 advanced gastric cancer patients treated with FP. Patients' performance status, oral intake, nausea/vomiting, diarrhea, fever, urine volume, presence of ascites or pleural effusion, laboratory data and administration of diuretics, corticosteroid and contents and volume of hydration before and during the first 5 days after chemotherapy were reviewed.The serum sodium level decreased after initiation of chemotherapy in all patients and the lowest level (nadir) was most frequently observed on day 8 (range, days 2-14), which preceded hematological toxicities. In 10 patients (20%) the nadir of serum sodium was lower than 125 mEq/l. We classified these 10 patients as a low-sodium group and the others into a normal-sodium group. Six (60%) and seven (70%) of the 10 patients in the low-sodium group had complications with grade 3 or 4 leukopenia and thrombocytopenia, whereas only one (3%) and two (5%) were seen in the normal-sodium group (p < 0.0001). Stomatitis and diarrhea were also slightly more severe in the former than the latter group. With respect to sensitivity and probability, receiver operating characteristic curves showed the nadir ((> or = ) or <125 mEq/l) of the serum sodium level was the best marker for both leukopenia and thrombocytopenia.RESULTSThe serum sodium level decreased after initiation of chemotherapy in all patients and the lowest level (nadir) was most frequently observed on day 8 (range, days 2-14), which preceded hematological toxicities. In 10 patients (20%) the nadir of serum sodium was lower than 125 mEq/l. We classified these 10 patients as a low-sodium group and the others into a normal-sodium group. Six (60%) and seven (70%) of the 10 patients in the low-sodium group had complications with grade 3 or 4 leukopenia and thrombocytopenia, whereas only one (3%) and two (5%) were seen in the normal-sodium group (p < 0.0001). Stomatitis and diarrhea were also slightly more severe in the former than the latter group. With respect to sensitivity and probability, receiver operating characteristic curves showed the nadir ((> or = ) or <125 mEq/l) of the serum sodium level was the best marker for both leukopenia and thrombocytopenia.Hyponatremia after initiation of chemotherapy with FP may be a warning sign of subsequent severe hematological toxicity.CONCLUSIONHyponatremia after initiation of chemotherapy with FP may be a warning sign of subsequent severe hematological toxicity. Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance. The subjects were 50 advanced gastric cancer patients treated with FP. Patients' performance status, oral intake, nausea/vomiting, diarrhea, fever, urine volume, presence of ascites or pleural effusion, laboratory data and administration of diuretics, corticosteroid and contents and volume of hydration before and during the first 5 days after chemotherapy were reviewed. The serum sodium level decreased after initiation of chemotherapy in all patients and the lowest level (nadir) was most frequently observed on day 8 (range, days 2-14), which preceded hematological toxicities. In 10 patients (20%) the nadir of serum sodium was lower than 125 mEq/l. We classified these 10 patients as a low-sodium group and the others into a normal-sodium group. Six (60%) and seven (70%) of the 10 patients in the low-sodium group had complications with grade 3 or 4 leukopenia and thrombocytopenia, whereas only one (3%) and two (5%) were seen in the normal-sodium group (p < 0.0001). Stomatitis and diarrhea were also slightly more severe in the former than the latter group. With respect to sensitivity and probability, receiver operating characteristic curves showed the nadir ((> or = ) or <125 mEq/l) of the serum sodium level was the best marker for both leukopenia and thrombocytopenia. Hyponatremia after initiation of chemotherapy with FP may be a warning sign of subsequent severe hematological toxicity. |
Author | Boku, N. |
Author_xml | – sequence: 1 givenname: N. surname: Boku fullname: Boku, N. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11574631$$D View this record in MEDLINE/PubMed |
BookMark | eNptkU1v1DAQhiNURD_gxB1ZHLigUDuJ88EFoajtIlWiYhdxtCbOZNcrx05tp3R_H38Mb7cgVHGakeZ5X83Me5ocGWswSV4z-oHRJj_fbqU93-yQ1vxZcsKKkqd5mbGjf_rj5NT7LaWU10X1IjlmjFdFmbOT5Nc3DM76CWVQd0iWYe53xA5ksZusgeBwVECUIVfgg1OStGAkOnIDQaEJnqwcQsCe_FRhQ4C0duxU1ClrSLvB0YYNOpgeLHl6qWfr7OxAKk3A9KRVftKRNh-j9sZ6rzqN5Ac4o8yaLNXa7IVLvEOHZIEjBKvtWknQZGXvlVRxC__pZfJ8AO3x1WM9S75fXqzaRXr99epL-_k6lXlehlTKpuu6oc9qlvXQZHkpeQG0AhrnwIuiR5k3kiOvZTFI3pV1CZgNsTZZL7v8LHl38J2cvZ3RBzEqL1FrMGhnLyqWUZrVdQTfPgG38WoTdxMZqxjNS95E6M0jNHcj9mJyagS3E3-yiQA7ADIG5B0OIt778NrgQGnBqNjnL_b5i0P-UfP-ieav7X_o32nRt78 |
CitedBy_id | crossref_primary_10_1007_s10388_018_0615_y crossref_primary_10_1080_21645515_2024_2414546 crossref_primary_10_1111_cas_12486 crossref_primary_10_1007_s00520_007_0309_9 crossref_primary_10_5981_jjhnc_40_38 crossref_primary_10_1111_ecc_12187 |
ContentType | Journal Article |
Copyright | Copyright Oxford University Press(England) Aug 1, 2001 |
Copyright_xml | – notice: Copyright Oxford University Press(England) Aug 1, 2001 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7T7 7TM 7TO 7U9 8FD C1K FR3 H94 K9. P64 7X8 |
DOI | 10.1093/jjco/hye085 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Virology and AIDS Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1465-3621 |
EndPage | 387 |
ExternalDocumentID | 376839061 11574631 10_1093_jjco_hye085 |
Genre | Journal Article |
GroupedDBID | --- -E4 .2P .55 .I3 .ZR 0R~ 18M 1TH 29J 2WC 3O- 4.4 482 48X 5GY 5RE 5VS 5WA 5WD 7.U 70D AABZA AACZT AAJKP AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAYXX ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNGD ABNHQ ABNKS ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUKT ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGKEF AGORE AGQPQ AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ASPBG ATGXG AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CAG CDBKE CITATION COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H5~ HAR HVGLF HW0 HZ~ IH2 IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN M-Z MHKGH ML0 N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y RD5 RNI ROX ROZ RUSNO RW1 RXO RZF RZO TCURE TEORI TJX TKC TR2 UDS W8F WOQ X7H X7M YAYTL YKOAZ YXANX ZKX ~91 .GJ 53G 6.Y AAJQQ AAPGJ AAWDT ABQTQ ABSAR ABSMQ ACFRR ACPQN ACUTJ ACZBC ADJQC ADRIX AEHUL AEKPW AFFQV AFSHK AFXEN AFYAG AGKRT AGMDO APJGH AQDSO AQKUS ATTQO BZKNY CGR CUY CVF ECM EIF EIHJH H13 M49 MBLQV NPM O~Y QBD R44 RHF TMA X7J ZGI 7T5 7T7 7TM 7TO 7U9 8FD C1K FR3 H94 K9. P64 7X8 |
ID | FETCH-LOGICAL-c336t-cc9bbbfd2812da9236c54a07a0c33a544dec39c5e58c4fc5b686ae2fb6892dcb3 |
ISSN | 1465-3621 0368-2811 |
IngestDate | Fri Jul 11 16:14:55 EDT 2025 Mon Jun 30 16:58:05 EDT 2025 Wed Feb 19 02:33:33 EST 2025 Tue Jul 01 04:34:53 EDT 2025 Thu Apr 24 23:08:01 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c336t-cc9bbbfd2812da9236c54a07a0c33a544dec39c5e58c4fc5b686ae2fb6892dcb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-2 content type line 23 |
PMID | 11574631 |
PQID | 217103659 |
PQPubID | 46566 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_71200288 proquest_journals_217103659 pubmed_primary_11574631 crossref_citationtrail_10_1093_jjco_hye085 crossref_primary_10_1093_jjco_hye085 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2001-08-01 |
PublicationDateYYYYMMDD | 2001-08-01 |
PublicationDate_xml | – month: 08 year: 2001 text: 2001-08-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Oxford |
PublicationTitle | Japanese journal of clinical oncology |
PublicationTitleAlternate | Jpn J Clin Oncol |
PublicationYear | 2001 |
Publisher | Oxford Publishing Limited (England) |
Publisher_xml | – name: Oxford Publishing Limited (England) |
SSID | ssj0005847 |
Score | 1.6279509 |
Snippet | Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with... Background: Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 382 |
SubjectTerms | Antineoplastic Combined Chemotherapy Protocols - adverse effects Cisplatin - adverse effects Drug Resistance, Neoplasm Female Fluorouracil - adverse effects Humans Hyponatremia - chemically induced Leukopenia - chemically induced Male Middle Aged Retrospective Studies ROC Curve Sodium - blood Stomach Neoplasms - drug therapy Thrombocytopenia - chemically induced |
Title | Retrospective Study of Hyponatremia in Gastric Cancer Patients Treated with a Combination Chemotherapy of 5-Fluorouracil and Cisplatin: a Possible Warning Sign of Severe Hematological Toxicities? |
URI | https://www.ncbi.nlm.nih.gov/pubmed/11574631 https://www.proquest.com/docview/217103659 https://www.proquest.com/docview/71200288 |
Volume | 31 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEuqDy7LQ8feqIKTeI8uSBYUZaiIgRb0VvkOLZIWZLVbiJR_hQ_gj_GTOxkk7JIhUsSORlvNvN5ZmzPg5B9zFFuZ0FgKcfJLI8rz4ojN7aUGyrm4kYfxwX9k_fB9NQ7PvPPRqOfPa-lukqfiR8b40r-h6vQBnzFKNl_4GzXKTTANfAXjsBhOF6Jxx9ltSzbWMnGJbDZL59eLHBNfCm_5RzXM95wLM4hDibI4SVm5c-buLYZGoyt-zlH0QDTZA0IzCNgYrOaLn3raF6XS3gpLnKdXWCSrxboSFfoeOkPJY6uuTz4bNZaPmHFTwyJkfBdJeg3sI07STsrv-eiSeZ6ybPwGJQ3FsXsp7ToojfLQgx2AV6VX2sdLjZYvHA617lW3nqBb4EO1U1yQ5sR0szpgTHqSVymaxcZ5c209v5DL-icWefnooTTlwtp6zpBw_zbl_Ri562o9-lZguSJJr5GrrthqP0C3r5b-xRFTUW77h-YgFAgPkTiQ008NIH-Mq9p7JvZNrllJib0pUbZbTKSxR1y48S4XtwlvwZgow3YaKloH2w0L6gBG9Vgoy3YqAEbRbBRTntgo32wYZdDsFEAG-3A9hxoW6hRAzWKUENCDTU6gBpdQ-3FPXJ69Ho2mVqmAoglGAsqS4g4TVOVuWCGZhzmIoHwPW6H3Ib73Pe8TAoWC1_6kfCU8NMgCrh0FZxjNxMpu0-2irKQO4QqMNdkJmKbha6HVQkc7qgoCyOuhBS2PSZPW6YkwqTHxyot82QD-8dkv3t4obPCbH5sr-VuYkbNKnEdMOpZ4Mdj8qS7CzIdN-pggJX1KgkddJ2KojF5oCGx_hHHD72AObtXe4E9cnM96h6SrWpZy0dgRFfp4wa4vwFWCNS6 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Retrospective+Study+of+Hyponatremia+in+Gastric+Cancer+Patients+Treated+with+a+Combination+Chemotherapy+of+5-Fluorouracil+and+Cisplatin%3A+a+Possible+Warning+Sign+of+Severe+Hematological+Toxicities%3F&rft.jtitle=Japanese+journal+of+clinical+oncology&rft.au=Boku%2C+N.&rft.date=2001-08-01&rft.issn=1465-3621&rft.eissn=1465-3621&rft.volume=31&rft.issue=8&rft.spage=382&rft.epage=387&rft_id=info:doi/10.1093%2Fjjco%2Fhye085&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_jjco_hye085 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-3621&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-3621&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-3621&client=summon |